Deals in Depth: May 2008
Executive SummaryMay 2008 dealmaking highlights: BMS stood out, getting a Phase II cardiovascular agent from KAI, selling off its ConvaTec wound healing division to private equity, and acquiring Kosan BioSciences; total private placement dollars in biopharma companies ($496mm) was almost half what it was in the previous month, while private investments in device players were up 67% to $278mm.
You may also be interested in...
The World Health Organization has proposed changes to its 2016 guideline on data integrity requirements to provide streamlined information to sponsors and to take account of experience gained to date.
The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.
No device-related warning letters were released by the US FDA the week of 10 December.